National Bank of Canada FI Reduces Stake in Illumina, Inc. (NASDAQ:ILMN)

National Bank of Canada FI lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 94.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,983 shares of the life sciences company’s stock after selling 32,114 shares during the quarter. National Bank of Canada FI’s holdings in Illumina were worth $265,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of ILMN. Bank of Stockton increased its holdings in Illumina by 3.8% during the 4th quarter. Bank of Stockton now owns 2,162 shares of the life sciences company’s stock worth $289,000 after purchasing an additional 80 shares during the period. Stephens Inc. AR grew its holdings in Illumina by 1.4% during the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock worth $885,000 after acquiring an additional 90 shares in the last quarter. Spire Wealth Management raised its holdings in shares of Illumina by 26.0% in the 4th quarter. Spire Wealth Management now owns 470 shares of the life sciences company’s stock valued at $63,000 after purchasing an additional 97 shares in the last quarter. IFP Advisors Inc lifted its position in shares of Illumina by 19.1% in the 4th quarter. IFP Advisors Inc now owns 617 shares of the life sciences company’s stock worth $82,000 after purchasing an additional 99 shares during the period. Finally, Brooklyn Investment Group increased its holdings in Illumina by 20.5% during the fourth quarter. Brooklyn Investment Group now owns 611 shares of the life sciences company’s stock valued at $82,000 after buying an additional 104 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Trading Down 6.6 %

ILMN opened at $71.26 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The company’s 50 day simple moving average is $89.57 and its two-hundred day simple moving average is $122.68. The firm has a market capitalization of $11.29 billion, a price-to-earnings ratio of -9.28, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ILMN has been the subject of several recent research reports. Citigroup reduced their price target on Illumina from $90.00 to $85.00 and set a “neutral” rating for the company in a research report on Monday. Stephens reiterated an “overweight” rating and set a $156.00 price objective on shares of Illumina in a report on Tuesday, March 11th. Royal Bank of Canada reduced their target price on Illumina from $128.00 to $112.00 and set an “outperform” rating on the stock in a research report on Tuesday. Guggenheim lowered their price target on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a report on Friday, February 7th. Finally, Canaccord Genuity Group decreased their price objective on shares of Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a research report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $138.70.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.